Success Metrics

Clinical Success Rate
85.3%

Based on 29 completed trials

Completion Rate
85%(29/34)
Active Trials
16(25%)
Results Posted
17%(5 trials)
Terminated
5(8%)

Phase Distribution

Ph phase_3
1
2%
Ph early_phase_1
1
2%
Ph phase_2
7
11%
Ph phase_1
8
13%
Ph not_applicable
24
38%

Phase Distribution

9

Early Stage

7

Mid Stage

1

Late Stage

Phase Distribution41 total trials
Early Phase 1First-in-human
1(2.4%)
Phase 1Safety & dosage
8(19.5%)
Phase 2Efficacy & side effects
7(17.1%)
Phase 3Large-scale testing
1(2.4%)
N/ANon-phased studies
24(58.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

78.4%

29 of 37 finished

Non-Completion Rate

21.6%

8 ended early

Currently Active

16

trials recruiting

Total Trials

63

all time

Status Distribution
Active(19)
Completed(29)
Terminated(8)
Other(7)

Detailed Status

Completed29
Recruiting13
unknown7
Terminated5
Active, not recruiting3
Withdrawn3

Development Timeline

Analytics

Development Status

Total Trials
63
Active
16
Success Rate
85.3%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (2.4%)
Phase 18 (19.5%)
Phase 27 (17.1%)
Phase 31 (2.4%)
N/A24 (58.5%)

Trials by Status

terminated58%
unknown711%
active_not_recruiting35%
completed2946%
recruiting1321%
withdrawn35%
not_yet_recruiting35%

Recent Activity

Clinical Trials (63)

Showing 20 of 63 trialsScroll for more
NCT04458883Not Applicable

The Next Leap in Cardiac Magnetic Resonance Imaging:Cycling the Field

Recruiting
NCT05761171Phase 2

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Active Not Recruiting
NCT02160015Phase 1

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Active Not Recruiting
NCT02811055Phase 2

Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin

Completed
NCT03258593Phase 1

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Completed
NCT05309655Not Applicable

Cardiac Outcomes With Near-Complete Estrogen Deprivation

Recruiting
NCT07387354Phase 1

Pacritinib With Aza for Upfront Myelodysplastic Syndrome

Not Yet Recruiting
NCT07456852Phase 1

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy

Not Yet Recruiting
NCT03830320Phase 1

Positron Emission Tomography (PET) Imaging of Thrombosis

Recruiting
NCT07058064Not Applicable

WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)

Recruiting
NCT05887271Phase 2

A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction

Recruiting
NCT06737380Phase 1

UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients

Recruiting
NCT05201014

Cancer Survivor Cardiomyopathy Detection

Active Not Recruiting
NCT06386185

Developing the Probability Algorithm for Pulmonary Hypertension Echocardiography

Recruiting
NCT04221958

Surface ECG Mapping

Withdrawn
NCT06916949Not Applicable

Stress Evaluation and Management Using High Fidelity Simulation in Medical Education

Not Yet Recruiting
NCT05672134Phase 2

Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction

Completed
NCT06418633Not Applicable

Variations in the Hemostatic System Induced by a Standardized Walking Test

Recruiting
NCT05699915Not Applicable

Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors

Terminated
NCT05683873Not Applicable

Stroke-induced Myocardial Dysfunction: Role of GDF-15 (SMOG-15) Clinical Work Package

Recruiting

Drug Details

Intervention Type
PROCEDURE
Total Trials
63